Bellus Health Inc. - a GSK company

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Bellus Health Inc. - a GSK company sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Bellus Health Inc. - a GSK company: 9 sponsored US clinical trials, 1 recruiting.

Bellus Health Inc. - a GSK company sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cough, with 3 trials.

Top-decile sponsor footprint

Bellus Health Inc. - a GSK company ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
ACTIVE NOT RECRUITING Phase 3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191
COMPLETED Phase 1

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

NCT06497517
COMPLETED Phase 1

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

NCT06222892
COMPLETED Phase 2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
COMPLETED Phase 2

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT04678206
TERMINATED Phase 2

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638
COMPLETED Phase 2

Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy

NCT00056238
COMPLETED Phase 2

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 2

Therapeutic Areas

Cough 3
Refractory Chronic Cough 2
Neurologic Diseases, General 1
Chronic Pruritus 1
Atopic Dermatitis 1
Stroke 1

What is open in the Bellus Health Inc. - a GSK company pipeline

1 recruiting of 9 indexed (11% open); 6 completed (67%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Cough (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Bellus Health Inc. - a GSK company: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Bellus Health Inc. - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Bellus Health Inc. - a GSK company4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Bellus Health Inc. - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bellus Health Inc. - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bellus Health Inc. - a GSK company page

9 registered trials is a research-attention snapshot, not an endorsement of Bellus Health Inc. - a GSK company or any single study.

  • 1 of Bellus Health Inc. - a GSK company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cough is the condition Bellus Health Inc. - a GSK company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cough trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bellus Health Inc. - a GSK company pipeline card: 9 registered trials from official public datasets.Report a data error.